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Abstract
Background: Cognitive Behavioural Therapy (CBT) reduces distress in multiple sclerosis, and helps manage
adjustment, but cost-effectiveness evidence is lacking.
Methods: An economic evaluation was conducted within a multi-centre trial. 94 patients were randomised to
either eight sessions of nurse-led CBT or supportive listening (SL). Costs were calculated from the health, social and
indirect care perspectives, and combined with additional quality-adjusted life years (QALY) or improvement on the
GHQ-12 score, to explore cost-effectiveness at 12 months.
Results: CBT had higher mean health costs (£1610, 95% CI, −£187 to 3771) and slightly better QALYs (0.0053, 95%
CI, −0.059 to 0.103) compared to SL but these differences were not statistically significant. This yielded £301,509 per
QALY improvement, indicating that CBT is not cost-effective according to established UK NHS thresholds. The extra
cost per patient improvement on the GHQ-12 scale was £821 from the same perspective. Using a £20,000,
threshold, CBT in this format has a 9% probability of being cost effective. Although subgroup analysis of patients
with clinical levels of distress at baseline showed an improvement in the position of CBT compared to SL, CBT was
still not cost-effective.
Conclusion: Nurse delivered CBT is more effective in reducing distress among MS patients compared to SL, but is
highly unlikely to be cost-effective using a preference-based measure of health (EQ-5D). Results from a disease-
specific measure (GHQ-12) produced comparatively lower Incremental Cost-Effectiveness Ratios, but there is
currently no acceptable willingness-to-pay threshold for this measure to guide decision-making.
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Background
The clinical effects of multiple sclerosis (MS) and subse-
quent ambulatory complications associated with man-
aging the condition may have psychological effects,
which may not necessarily be treated with drugs. MS pa-
tients report very high levels of emotional distress and
levels of major depression as high as 20% annually and
50% over a lifetime [1–3]. Depression in MS patients has
been linked to disability, negative effects on quality of
life, self-harming tendencies, as well as low adherence,
which may eventually result in the discontinuation of
disease modifying therapies (DMTs) [4, 5]. However, ele-
vated levels of distress or comorbid psychological disor-
ders in MS are often overlooked in treatment [6]. There
are particularly stressful moments in the trajectory of
the illness (such as MS diagnosis, relapse, disease pro-
gression) and other critical life changing events when el-
evated levels of distress are to be expected [7].
Treating depression appears to improve adherence to
Interferon beta-1B [8], and cognitive behavioural therapy
(CBT) is increasingly being used to manage symptoms
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and enhance psychosocial outcomes for people with
chronic conditions [7, 9, 10]. In MS, there is evidence
that CBT may be helpful in reducing depression, anxiety,
fatigue, disability, problems in dealing with cognition in
addition to improving quality of life [7, 10–14]. A recent
meta-analysis suggested psychological interventions
(most of which were CBT-based) were at least moder-
ately effective in treating depression in MS [14]. To date
only one trial [15] has reported on the cost-effectiveness
of a psychological adjustment group therapy for MS, and
due to the significant amount of missing data in the
quality of life data, quality-adjusted-life-years (QALYs)
were not estimated, and the Beck Depression Inventory-
II was used to report a cost per point reduction on the
scale of £118. Two pilot studies showed that web based
CBT and SKYPE delivered mindfulness groups [16] may
have the potential to be cost-effective in reducing fatigue
and distress in MS respectively. However, these studies
had no long-term follow up and data are preliminary.
A randomised controlled trial (RCT) of a nurse-led
cognitive behavioural therapy for adjusting in the early
stages of multiple-sclerosis reported that CBT is more
effective in reducing distress for MS patients compared
to supportive listening (SL) [17] up to one year follow
up. The gains for CBT were also significantly greater for
those who had clinically significant levels of distress at
baseline. This paper reports on a cost-effectiveness study
nested within this trial. We explored both cost-
effectiveness and cost utility in the whole cohort. We
also conducted a subgroup analysis of patients who en-
tered the trial with clinically significant levels of distress.
Methods
Design and setting
The study was a two-arm, randomised, multicentre
parallel-group controlled trial. Patients were recruited
from MS centres in Hampshire and South London, and
randomly assigned to receive either CBT or SL. Full de-
tails of the trial methods, intervention components and
findings have been reported previously [10, 18].
Interventions
Both interventions were delivered by general nurses spe-
cifically trained to provide eight one-on-one sessions,
over a 10-week period. The sessions were delivered as a
combination of two face-to-face meetings and six tele-
phone calls.
Self-reported outcomes
Patients completed detailed measures at baseline,
15 weeks (end of treatment), 6 and 12 months post-
randomisation with 12 months being the primary
outcome point. The primary outcome was adjustment
(defined as psychological well-being) measured using the
General Health Questionnaire (GHQ-12) [19]. The
GHQ-12 uses a Likert scoring method, where high
scores indicate higher distress, and to allow for a mean-
ingful cost-effectiveness analysis, the GHQ 12 score was
reported as a change score, multiplied by −1 to get an
inverted score in which higher figures denote better
outcomes.
Quality of life was assessed using (EQ-5D-3L) [20].
EQ-5D-3L is a brief self-reported preference-based
measure which considers five dimensions of health (mo-
bility, self-care, usual activities, pain/discomfort and anx-
iety/depression) each consisting of three levels of
functioning (e.g. the levels for the pain dimension are no
pain, moderate pain and extreme pain). This measure
produces a possible 243 distinct health states ranging
from 11111 (full health) to 33333 (worst) [21]. Value sets
estimated from general population based studies were
applied to the health states to produce preference-based
scores between 0 (worse health) and 1 (full health). The
measure also has a visual analogue scale ranging from 0
(the worst health you can imagine) to 100 (the best
health you can imagine). Quality-adjusted-life-years
(QALYS) were derived from transformed EQ-5D-3L
scores, using the area-under-the-curve method [22].
Service use and costs
Contacts with the CBT and SL interventions were cen-
trally recorded. Self-reported six-month retrospective
health and social services data were collected at baseline,
six- and 12-month follow-up, using an adapted version
of the Client Service Receipt Inventory (CSRI) [23]. To
ensure we captured relevant services the CSRI was
adapted based on available literature and expert guid-
ance. Patients provided details of their retrospective use
of medication, inpatient, out-patient appointments, la-
boratory tests and scans, emergency department, contact
with community professionals (GPs, neurologists, etc.)
and informal care including access to social welfare
benefits.
Service use was combined with nationally applicable
unit costs [24–26] to derive total costs. Costs were mea-
sured in UK prices (£) for 2008/09, and given the one-
year time horizon, there was no need to discount either
costs or effects. Interventions costs were estimated by
multiplying the unit cost of nurses providing the inter-
vention by the number of sessions attended. Informal
carers are not paid for their support to patients but there
is still a value to this time. Informal care cost was esti-
mated using the unit cost of a local authority home care
worker as a proxy value [24]. Productivity costs were es-
timated through the human capital approach, which in-
volves applying national wage rates to days off work due
to illness.
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Statistical analysis
Data were analysed using Stata 11 and patients were
assessed using an intention-to-treat analysis. Missing
costs and QALY data were imputed using a
regression-based method adjusting for baseline vari-
ables costs, EQ-5D-3L scores, GHQ-12 score, and the
type of MS. Non-parametric bootstrapping methods
were used to account for non-normality in the distri-
bution of cost data [27]. Outcomes and costs were
presented as mean values with standard deviations,
and compared between groups at baseline and 12-
months follow-up.
The economic evaluation was conducted from both
a health and social care, and societal perspectives. If
one intervention had lower costs and better outcomes
than the comparator, then it would be considered
‘dominant’. In the event of the intervention having
higher costs and better outcomes, cost-effectiveness
would be assessed using incremental cost-effectiveness
ratios (ICERs).
Cost-effectiveness planes (CEP) and cost-effectiveness
acceptability curves (CEAC) were created to address the
uncertainty around points estimates of the ICERs. For
the CEP plane, non-parametric bootstrapping was used
to create a joint distribution of incremental costs and
outcomes, and plotting these differences on a scatter
plot (one axis represents incremental costs and the other
incremental outcome), to show the probability of the
intervention being (i) cost-saving and more effective, (ii)
cost-saving and less effective, (iii) cost-increasing and
more effective and (iv) cost-increasing and less effective.
The probability of the intervention being cost-effective
was explored through the use of cost-effectiveness ac-
ceptability curve (CEAC), which were created by calcu-
lating a series of net benefits for a range (£0–£60,000) of
plausible values defined as a decision maker’s willingness
to pay for an additional unit improvement of health out-
comes (e.g. QALYs) [28].
Sub-group analysis
The concurrent trial found that patients who had clinic-
ally significant distress at baseline showed meaningfully
greater benefits from CBT over SL than those who were
not distressed [7]. We conducted a sub-group analysis
exploring cost-effectiveness for the distressed only, i.e.
patients who scored three and above on GHQ-12 using
the GHQ 0011 scoring method [29].
Results
Descriptive and clinical characteristics of participants
48 participants were randomised to CBT and 48 to SL.
Patient characteristics at baseline were broadly similar
across groups (Table 1), except that the SL group had a
slightly higher mean age (43.1 vs. 40.3); were more dis-
tressed (GHQ-12), disabled (EDSS scores), with slightly
lower quality of life scores (EQ-5D-3L). The proportion
(23%) reporting use of antidepressants was higher for
the CBT group (25 vs. 22), and more than half (60.6%)
had clinically significant distress levels.
Service use and costs
There were minimal differences in service use between
the two groups. Participants accessed a wide range of
health and social care services (Table 2), but the most in-
tensively used were the GP (84% at baseline) and MS
nurse (82% at baseline), followed by neurologists (66%).
The proportion with GP contacts had decreased by 12-
month follow-up for both groups. The percentage in con-
tact with neurologists and MS nurses was reduced over
the follow-up period, with more reductions evident in the
SL group for neurologists. Most participants reported the
use of at least one medication (particularly disease modify-
ing therapies) in both groups at baseline. Physiotherapists
and alternative therapists had consistently low use over
the entire study period for both groups.
Despite low admissions (10%), the CBT group had sub-
stantially more inpatient days at 12 months. More than
Table 1 Baseline characteristics of participants
CBT (n = 48) SL (n = 46)
Mean(S.D.) Mean(S.D.)
Mean age in years (SD) 40.3 (8.6) 43.1 (10.1)
Number of female participants (%) 35 (72.9) 30 (65.2)
Number of Married/cohabiting participants (%) 30 (62.5) 24 (52.2)
Number of White British participants (%) 38 (79.2) 33 (71.7)
Number of participants with A level or higher (%) 35 (72.9) 30 (65.2)
Mean EDSS score (SD) 4.9 (1.4) 5.1 (1.0)
Mean GHQ score (SD) 14.0 (5. 5) 16.4 (6.8)
Mean EQ-5D score (SD) 0.66 (0.22) 0.60 (0.26)
Number treated for depression in the past year (SD) 12 (25) 10 (22)
Number diagnosed with relapsing remitting MS (SD) 37 (77) 36 (78)
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two thirds (71%) reported investigations (e.g. blood tests,
MRI, x-rays, CT/CAT and EEGs) at baseline, but at
follow-up the proportions had decreased for both
groups. The mean number of tests remained the same
(2.5) for the CBT group, but had decreased (1.6) for the
SL group. Almost all (99%) patients reported informal
care at baseline, and while this had decreased at follow-
up, the mean hours/week were not so different. The
mean cost of CBT was £307 compared to £306 for SL
over 12 weeks. At baseline, mean service costs were
fairly similar between the groups (Table 3), but higher
informal care costs for the CBT group (£4378 vs. £2903),
contributed to much more societal costs at baseline
compared to the SL group. Over the whole follow-up
period, mean costs were higher in the CBT group. Drug
costs contributed the highest share to health and social
care costs while informal care added the greatest propor-
tion to societal costs. Although the number receiving in-
formal care were similar, the CBT group had greater
intensity of use hence higher costs. From the health and
social care (NHS) perspective CBT had higher mean costs
at follow-up compared to SL (£7331 vs. £5026), but this
difference, adjusted for baseline costs (£1610) was not sta-
tistically significant (bootstrapped 95% CI, −£187 to 3771).
The difference in mean costs from the societal perspective
(£2871), was also not statistically significant (bootstrapped
95% CI, −£2028 to £7793).
Cost-effectiveness analysis and cost-utility-analyses
At baseline GHQ-12 scores were lower for the CBT group
(13.98 vs. 16.40), and at 12 months both groups showed re-
ductions in distress but the improvement in mean scores
was better for the CBT group (2.69 vs. 1.97) and the differ-
ence(1.9572) statistically significant (bootstrapped 95% CI,
−5.41 to −1.05) [17]. Based on the change score, CBT pro-
duced an ICER of £821/GHQ-12 score compared to SL
from the health and social care perspective, indicating that
for a one-point improvement on the GHQ-12 the NHS
should pay £821. The ICER from the societal perspective is
£1242/GHQ-12.
QALY results were also better for the intervention
group at 12 months (0.6627 vs. 0.6197) but the differ-
ence (0.0053) was not statistically significant (boot-
strapped 95% CI, −0.059 to 0.103). CBT was therefore
more effective at improving quality of life, but expensive,
yielding an ICER of £303,774 from the health and social
care perspective and £541,698 from the societal
perspective.
Subgroup analysis of those with clinical levels of distress at
baseline
Results from the subgroup analysis revealed a mean cost
difference of £1362 (bootstrapped 95% CI, −781 to 3612)
from the NHS perspective and £3506 (bootstrapped 95%
CI, −2704 to 9611) from the wider societal perspective.
A statistically significant difference in the GHQ12 score
(4.257 bootstrapped at 95% CI, 1.109 to 7.521) produced
a corresponding ICER of £320 from the NHS perspective
and £825 from the societal perspective.
For the same analysis, a mean difference in QALYs of
0.0108 (bootstrapped 95% CI, −0.051 to 0.068) indicates
that the NHS would have to pay £126,111 for an add-
itional QALY, while the society pays £324,630. Both
these figures are higher than the UK cost-effectiveness
threshold, but are substantially lower than the ICER in
the base-case analysis.
The Cost-Effectiveness Plane (CEP) (Fig. 1) illustrates
uncertainty around the estimated ICERs and it shows
Table 3 Summary of service costs and outcomes at baseline, six and twelve months
Treatment A (CBT) n = 48 Treatment B (Supportive listening) n = 46
Cost category baseline 6 months 12 months baseline 6 months 12 months
Mean (S.D) Mean (S.D) Mean (S.D) Mean (S.D) Mean (S.D) Mean (S.D)
Intervention 0 307 (170) 0 0 306 (148) 0
Medication (drugs) 2079 (1938) 2724 (3427) 2531 (4656) 1928 (2373) 1476 (2094) 1882 (2644)
Community services (contacts with professionals) 657 (1130) 422 (430) 483 (715) 466 (402) 305 (331) 395 (482)
Hospital services 185 (559) 133 (692) 204 (956) 96 (340) 91 (393) 119 (466)
Investigations 79 (148) 35 (77) 33 (78) 78 (123) 20 (60) 15 (43)
Total hospital and social care costs 3000 (2098) 3621 (3751) 3251 (5134) 2568 (2295) 2198 (2507) 2412 (2654)
Informal care 4378 (6970) 3807 (7463) 4162 (6352) 2903 (4550) 2192 (4993) 4064 (6242)
Productivity loss 1096 (2726) 704 (3151) 388 (1742) 719 (2471) 147 (428) 385 (1987)
Total societal costs 8473 (8212) 8132 (9036) 7802 (8819) 6190 (6183) 4538 (5605) 6862 (6922)
Social benefits 1210 (1282) 1430 (1320) 1229 (1349) 1325 (1259) 1360 (1448) 1640 (1562)
EQ-5D score 0.659 (0.215) 0.661 (0.216) 0.644 (0.267) 0.595 (0.262) 0.641 (0.198) 0.622 (0.274)
GHQ-12 13.977 (5.449) 11.289 (4.63) 16.391 (6.771) 14.422 (7.316)
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most (58%) of the scatter points fall on the north-east
quadrant which implies that CBT produces higher costs
and better QALYs. The £20,000 threshold line has very
few points below it, indicating that the probability of
cost-effectiveness is likely to be very low at that
willingness-to-pay threshold. The CEAC (Fig. 2) demon-
strates the probability of the intervention being cost-
effective at varying willingness-to-pay thresholds per
improvement in QALYs. Adjusted for baseline costs and
utility scores, the CEAC indicates a 9% probability of
CBT being cost-effective at £20,000/QALY from the
health and social care perspective, which confirms the
CEP findings. The second CEP (Fig. 3) produced using
the GHQ-12 score and cost from a similar perspective,
however show 91% of the bootstrapped ICERs falling on
the north-east quadrant, indicating that CBT is better at
reducing psychological distress, albeit at higher costs,
compared to SL.
Discussion
We have established that nurse-led CBT produces
slightly better QALYs and is more effective in reducing
psychological distress for MS, compared to SL. However,
when the small effects are combined with incremental
costs, CBT is not considered cost-effective compared to
SL, according NICE guidelines. This conclusion was
drawn from results of the ICER based on the EQ-5D-3L
which show a cost per QALY of £303,774 from the
health and social care perspective and £541,698 from the
societal perspective. Sub-group analysis of patients meet-
ing thresholds for clinical distress at baseline indicates a
large improvement in the ICER (£126,111) from the
NHS and societal (£324,629) perspectives, but still sub-
stantially higher than the recommended threshold in the
UK. Results of the CEAC are also consistent with the
ICER, showing only a 9% probability for CBT being
cost-effective at the £20, 000 threshold when compared
with SL. Comparatively, the GHQ-12 results produced
much lower ICERs from both the health and social care
(£821), and the societal perspective (£1242). These fig-
ures are even lower when only the distressed group is
analysed; £320/GHQ-12 from the NHS perspective and
£825 from the societal perspective.
The difference in the ICERs is mainly driven by incre-
mental differences in the outcome measures, whereupon
the GHQ-12 detected sizeable differences and the EQ-
5D-3L produced very minimal differences. This could
point to the insensitiveness of the EQ-5D-3L in patients
with MS for all the five domains as illustrated in other
previous work [30–32]. It is also possible that the EQ-
Fig. 1 Cost-effectiveness plane of CBT compared to SL using QALYs, adjusted for baseline costs and utility, from the NHS perspective
Fig. 2 Cost-effectiveness acceptability curve of CBT compared to SL,
adjusted for baseline costs and utility, from the NHS perspective
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5D-3L is unable to detect the treatment effects of psy-
chological interventions in MS patients. This is substan-
tiated by previous work [15], in which the EQ-5D-3L
failed to detect an effect in mood for MS patients. The
sample size was estimated based on the primary clinical
outcome, and it is possible that it was underpowered to
demonstrate a significant difference in cost-effectiveness.
These results can assist in guiding researchers and
policy-makers on areas to prioritise when considering
interventions for MS patients.
As far as we know, this is the first economic evalu-
ation of CBT for adjusting to multiple sclerosis. Whilst
CBT has been found to be cost-effective in other disease
areas such as depression [33], our results indicate that
investing in nurse-led CBT may not proffer value for
money compared to the same number of sessions of
nurse-led SL for MS patients.
More work needs to be done to explore the potential
cost-effectiveness of CBT in MS. Providing booster sessions
at follow up may improve quality of life gains as the treat-
ment effect for CBT at the end of treatment was greater
than at follow-up [17]. It is also possible that there are sub-
groups within MS patients that could be targeted for future
trials. It may be that future clinical trials target the therapy
to those who need it most, like people with less social sup-
port or those screened and found to be distressed. Al-
though our subgroup analysis did not produce cost-
effective results, other studies [15] reported clinical and
cost-effectiveness of group psychological therapy for MS
patients with low mood. The control group in Humphreys
et al. [15], unlike ours, received usual care (without psycho-
logical interventions), which is a closer reflection of the
current reality. Most patients with MS do not receive
formal therapy for their distress so it may be that compared
to treatment as usual, SL or CBTcould be cost effective op-
tions. More work is needed to test this hypothesis.
Limitations
Limitations of the trial are outlined in our clinical paper
[17], but the economic study had its own specific chal-
lenges. As is common in economic evaluations, there is
a possibility of recall bias as participants reported on six
months’ retrospective service use. There is ongoing de-
bate relating to the appropriateness of collecting re-
source use data, and for this trial the most pragmatic
method was self-report and the recall period was deter-
mined by the trial design. There is currently no societal
value linked to a unit improvement on the GHQ-12
score, making it hard to advice on the cost-effectiveness
of CBT using this measure.
We used data from a clinical trial for our economic ana-
lysis. Sample size calculations in trials are generally based
on the primary clinical outcome and not costs. However,
most economic evaluations (including this one) focus on
probabilities rather than testing for statistical significance
in cost-effectiveness. Having said that, small samples do
mean that we need to be cautious in our interpretation of
findings and this small sample size is a limitation. We have
referred to this in the discussion.
Conclusion
Nurse-led CBT compared to SL is not cost-effective for
adjustment to MS using EQ-5D-3L but produces reason-
able ICERs using GHQ-12. However, there is currently
no acceptable willingness-to-pay threshold for this meas-
ure to guide in decision-making.
Fig. 3 Cost-effectiveness plane using GHQ-12 change scores for CBT compared to SL, adjusted for baseline GHQ-12 score and costs, from
the NHS perspective
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Implications for health care provision and use, health
policies, and future research
Further research in this area could be directed at design-
ing CBT trials targeted to those who need it most, such
as people with distress, as well as using alternative utility
measures validated for psychological interventions in
MS patients. We also know little about the cost-
effectiveness of different levels of clinical expertise. In
this study, senior nurses who received a two-month
training course provided the CBT. It is possible that ex-
perienced clinical psychologists, although costlier, may
facilitate larger treatment effects and cost savings. Fi-
nally, recent evidence [34] suggests online therapy for
depression may be an effective treatment in MS. Provid-
ing minimal therapy support alongside online therapy
may be a cost-effective solution.
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